Comparison of Fate Therapeutics Inc. (FATE) and Gritstone Oncology Inc. (NASDAQ:GRTS)

Both Fate Therapeutics Inc. (NASDAQ:FATE) and Gritstone Oncology Inc. (NASDAQ:GRTS) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fate Therapeutics Inc. 4.74M 249.71 66.60M -1.23 0.00
Gritstone Oncology Inc. N/A 3015.75 64.81M -2.28 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Fate Therapeutics Inc. and Gritstone Oncology Inc.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Fate Therapeutics Inc. -1,405.06% -68.6% -50.3%
Gritstone Oncology Inc. 0.00% 0% 0%


Fate Therapeutics Inc. has a Current Ratio of 9.4 and a Quick Ratio of 9.4. Competitively, Gritstone Oncology Inc.’s Current Ratio is 6.1 and has 6.1 Quick Ratio. Fate Therapeutics Inc.’s better ability to pay short and long-term obligations than Gritstone Oncology Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Fate Therapeutics Inc. and Gritstone Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Fate Therapeutics Inc. 0 1 3 2.75
Gritstone Oncology Inc. 0 0 1 3.00

The average target price of Fate Therapeutics Inc. is $18.5, with potential upside of 1.59%. Gritstone Oncology Inc. on the other hand boasts of a $17 average target price and a 70.51% potential upside. Based on the data delivered earlier, Gritstone Oncology Inc. is looking more favorable than Fate Therapeutics Inc., analysts view.

Institutional & Insider Ownership

Roughly 97.3% of Fate Therapeutics Inc. shares are owned by institutional investors while 59.7% of Gritstone Oncology Inc. are owned by institutional investors. 1% are Fate Therapeutics Inc.’s share owned by insiders. Comparatively, Gritstone Oncology Inc. has 2.3% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Fate Therapeutics Inc. -0.43% 7% 17.82% 30.23% 42.48% 26.27%
Gritstone Oncology Inc. 6.08% 2.27% -46.26% 0% 0% -15.28%

For the past year Fate Therapeutics Inc. has 26.27% stronger performance while Gritstone Oncology Inc. has -15.28% weaker performance.


Gritstone Oncology Inc. beats Fate Therapeutics Inc. on 7 of the 11 factors.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.